We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

002648:SZSESatellite Chemical Co. Ltd. Class A Analysis

Data as of 2026-06-14 - not real-time

CN¥24.16

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Satellite Chemical trades at CNY 24.16, well below its DCF‑derived fair value of CNY 26.58, implying roughly a 10% intrinsic upside. The stock’s forward PE of 8.55 versus a trailing PE of 13.9 places it on the cheap side of the specialty‑chemical peer group. A modest revenue growth rate of 2.8% is complemented by a sharp EPS outlook, with forward EPS of 2.82 CNY versus trailing 1.74 CNY, indicating strong earnings momentum. Technicals show a bullish MACD histogram (+0.09) and a “bullish” MACD signal, while the price sits just under the 20‑day SMA (24.35) but comfortably above the support level of 22.68 CNY. The RSI of 43.9 and a neutral trend suggest the stock is not overbought, leaving room for further upside toward the resistance at 28.65 CNY. Dividend sustainability is solid, with a 2.07% yield and a low payout ratio of 28.7%, backed by robust free cash flow of CNY 7.18 bn.
However, the company carries a high debt‑to‑equity ratio of 76.8% and operates in a sector subject to stringent environmental regulations, which elevates regulatory and financial risk. Volatility is elevated at 39.8% over the past 30 days, though the beta of –0.12 (computed) and 0.54 (exchange) points to limited market‑wide correlation. Geographic exposure is concentrated in China, making the stock sensitive to domestic policy shifts, yet the domestic market provides a stable liquidity base with stable trading volumes. Analyst consensus targets (mean CNY 37.47, median CNY 36.85) imply a potential upside of over 50%, reinforcing the undervalued assessment. In summary, the blend of attractive valuation, earnings upside, and dividend safety outweighs the sector and regulatory headwinds for investors with a medium‑ to long‑term horizon. Short‑term traders may consider a cautious buy, while longer‑term holders can view the stock as a compelling addition to a growth‑oriented, value‑balanced portfolio.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Bullish MACD crossover with positive histogram
  • Price near 20‑day SMA and above support level
  • Attractive dividend yield with low payout ratio

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Forward EPS growth of ~62% and low forward PE
  • DCF fair value indicates intrinsic upside
  • Analyst target prices imply >50% upside

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Long‑term demand from EV, aerospace, and green infrastructure
  • Strong free cash flow supporting dividend sustainability
  • Undervalued valuation metrics relative to sector peers

Key Metrics & Analysis

Financial Health

Revenue Growth2.80%
Profit Margin12.62%
P/E Ratio13.9
ROE17.39%
ROA7.12%
Debt/Equity76.81
P/B Ratio2.3
Op. Cash FlowCN¥10.2B
Free Cash FlowCN¥7.2B

Technical Analysis

TrendNeutral
RSI43.9
SupportCN¥22.68
ResistanceCN¥28.65
MA 20CN¥24.35
MA 50CN¥26.49
MA 200CN¥21.67
MACDBullish
VolumeStable
Fear & Greed Index89.86

Valuation

Fair ValueCN¥26.58
Target PriceCN¥37.47
Upside/Downside55.09%
GradeUndervalued
TypeBlend
Dividend Yield2.07%

Risk Assessment

Beta-0.12
Volatility39.77%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.